Could a diabetes pill save lives in septic shock?
NCT ID NCT07488689
First seen Apr 18, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This study tests whether dapagliflozin, a diabetes drug, can improve survival and organ function in people with septic shock who have poor blood flow in small vessels. About 568 adults in the ICU will receive either the drug or a placebo, plus standard care, for up to 28 days. The goal is to see if the drug helps repair blood vessel damage and reduces complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Civil, Service de médecine intensive et réanimation, Hôpitaux Universitaires de Strasbourg
Strasbourg, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.